Tiffany is Founder and CEO of BiVictriX Therapeutics, a biotechnology company applying a novel approach to develop next generation cancer therapies using insights derived from frontline clinical experience.
Tiffany is one of the UK’s youngest CEOs of a publicly-listed company, having successfully listed the company on the AIM, London’s junior market, in November 2021.
She hails from Wigan and obtained a First Class honours degree in biochemistry and biomedicine from Lancaster University, followed by an MSc in Clinical Immunology from the University of Manchester. While working for the NHS as a clinical immunologist supporting the diagnosis of haematological malignancies, she was awarded the Chief Scientific Officer’s “Rising Star” award for her commitment to the delivery of healthcare.
This work also gave her the inspiration to start her own biotech company utilising Antibody Drug Conjugates (ADCs) through her own proprietary platform known as Bi-Cygni for the treatment of various cancers including Acute Myeloid Leukaemia. Tiffany has led BiVictriX since 2016 from its bases in Alderley Park, Cheshire and Wales.
She has been responsible for raising £10m in investment to date and has established a highly experienced scientific team at the company, significantly increasing the company’s internal capabilities and platform expertise.